Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Umbilical cord mesenchymal stem cell therapy - Sclnow Biotechnology

Next Previous
X
Search
Drug Profile

Umbilical cord mesenchymal stem cell therapy - Sclnow Biotechnology

Alternative Names: 19#iSCLife®-CSD; Cord blood stem cell therapy - Sclnow Biotechnology; hUC Mesenchymal Stem Cells - Sclnow Biotechnology; hUC-MSC; hUC-MSC - Sclnow Biotechnology; Human umbilical cord mesenchymal stem cells - Sclnow Biotechnology; SCLnow 19; Umbilical cord derived allogeneic mesenchymal stem cells therapy - Sclnow Biotechnology

Latest Information Update: 23 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sclnow Biotechnology
  • Class Antineoplastics; Heart failure therapies; Hepatoprotectants; Mesenchymal stem cell therapies; Stem cell therapies; Vascular disorder therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Wounds
  • Phase II Osteoarthritis; Primary ovarian insufficiency
  • Phase I Female infertility
  • No development reported Cerebral infarction; Femur head necrosis; Heart failure; Liver cirrhosis; Myelodysplastic syndromes

Most Recent Events

  • 17 Jul 2024 Phase-I clinical trials in Female infertility in China (Intrauterine) (NCT06503471)
  • 28 Nov 2023 No recent reports of development identified for phase-I development in Cerebral-infarction in China (IV, Injection)
  • 28 Nov 2021 No recent reports of development identified for phase-I development in Liver-Cirrhosis in China (IV, Injection)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top